↓ Skip to main content

Cancer immunotherapy: the beginning of the end of cancer?

Overview of attention for article published in BMC Medicine, May 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)

Mentioned by

19 tweeters
2 patents
3 Google+ users


304 Dimensions

Readers on

874 Mendeley
Cancer immunotherapy: the beginning of the end of cancer?
Published in
BMC Medicine, May 2016
DOI 10.1186/s12916-016-0623-5
Pubmed ID

Sofia Farkona, Eleftherios P. Diamandis, Ivan M. Blasutig


These are exciting times for cancer immunotherapy. After many years of disappointing results, the tide has finally changed and immunotherapy has become a clinically validated treatment for many cancers. Immunotherapeutic strategies include cancer vaccines, oncolytic viruses, adoptive transfer of ex vivo activated T and natural killer cells, and administration of antibodies or recombinant proteins that either costimulate cells or block the so-called immune checkpoint pathways. The recent success of several immunotherapeutic regimes, such as monoclonal antibody blocking of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD1), has boosted the development of this treatment modality, with the consequence that new therapeutic targets and schemes which combine various immunological agents are now being described at a breathtaking pace. In this review, we outline some of the main strategies in cancer immunotherapy (cancer vaccines, adoptive cellular immunotherapy, immune checkpoint blockade, and oncolytic viruses) and discuss the progress in the synergistic design of immune-targeting combination therapies.

Twitter Demographics

The data shown below were collected from the profiles of 19 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 874 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 <1%
Chile 1 <1%
Germany 1 <1%
Australia 1 <1%
France 1 <1%
India 1 <1%
Italy 1 <1%
Denmark 1 <1%
Japan 1 <1%
Other 2 <1%
Unknown 862 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 179 20%
Student > Ph. D. Student 172 20%
Student > Master 152 17%
Researcher 106 12%
Unspecified 103 12%
Other 162 19%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 210 24%
Agricultural and Biological Sciences 136 16%
Unspecified 131 15%
Medicine and Dentistry 116 13%
Immunology and Microbiology 90 10%
Other 191 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2019.
All research outputs
of 13,703,906 outputs
Outputs from BMC Medicine
of 2,162 outputs
Outputs of similar age
of 261,428 outputs
Outputs of similar age from BMC Medicine
of 2 outputs
Altmetric has tracked 13,703,906 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,162 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.1. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,428 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them